Operating, investing, and financing cash movements
Roivant Sciences generated -$750.3M in operating cash flow over the trailing twelve months. After $14.0M in capital expenditures, free cash flow was -$758.6M. Free cash flow increased 0.1% year-over-year. Based on the Q1 2026 filing.